

SHORT COMMUNICATION**Training in France**

We welcome the paper *Training in Paediatric Clinical Pharmacology* and would like to inform readers of the current situation in France in this speciality. There are currently three full-time paediatric clinical pharmacologists in France:

- Elisabeth Autret-Leca in Hôpital Bretonneau (Tours)
- Evelyne Jacqz-Aigrain in Hôpital Robert Debre (Paris VII)
- Gerard Pons in Groupe Hospitalier Cochin-St Vincent de Paul (Paris V)

All three are fully trained paediatricians who have completed an official training course in clinical pharmacology and are currently professors of clinical pharmacology.

Since 1991 a course in paediatric clinical pharmacology has been organised each year by ourselves in France.

Participating universities throughout France include Bordeaux II (Jean-Louis Demarquez), Nancy I (Marie-Jeanne Boutroy), Paris V (Gerard Pons), Paris VI (Daniel Vasmant), Paris VII (Evelyne Jacqz-Aigrain), Rouen (Eric Mallet) and Tours (Elisabeth Autret-Leca):

The duration of the course is 12 days (80 hours) and it covers the following areas:

Specific Aspects of Paediatric Pharmacology

- Pre-clinical studies
- Pharmacokinetics and pharmacodynamics
- Methodological aspects during the different phases of drug development
- Drug development in children

Clinical Trials

- Ethics – informed consent
- Pharmaceutical formulations for children
- Clinical trials: methodology, organisation, good clinical practices, etc

- Role of the pharmacist in clinical trials
- Role of the paediatrician/investigator in clinical trials
- Statistical analysis
- Analysis of the results of a clinical trial
- Critical analysis of a clinical trial
- Development of orphan drugs
- Role of the Drug Agency in drug evaluation and recommendations on drug use in children

Pharmacovigilance and Pharmacoepidemiology

- Case-controlled studies
- Specific aspects of pharmacovigilance in children

Pharmacokinetics and Therapeutic Drug Monitoring

- Using immunosuppressants as an example

Pharmacogenetics and Maturation***Pharmacoeconomics******Drugs in Pregnancy***

- Placental transfer
- Teratogenicity, fetal drug exposure
- Fetal drug therapy
- Drugs in breast milk

Drug Evaluation in Different Therapeutic Areas in Children

- Antibiotics
- HIV drugs
- Vaccines
- Drugs for asthma
- Anticonvulsants
- Analgesics

- Antipyretic agents
- Cytotoxic drugs
- Drugs for endocrine disorders involving children
- Antihypertensive agents
- Growth hormone
- Inhaled nitric oxide
- Surfactants

Over the last six years, 128 students have received training on the course. The majority of these were physicians and pharmacists. French-speaking readers who are interested in attending the course should contact either Professor Gerard Pons at Service de Pharmacologie Clinique, Hôpital Saint-Vincent de Paul, 82, avenue Denfert-Rochereau, 75674 Paris Cedex 14, France, or Evelyne Jacqz-Aigrain at Hôpital Robert Debré, 48 Boulevard Sérurier, 75019 Paris, France.

Elisabeth Autret-Leca, Tours, France

Gerard Pons, Paris, France

Evelyne Jacqz-Aigrain, Paris, France

Marie-Jeanne Boutroy, Nancy, France

Eric Mallet, Rouen, France

Jean-Louis Demarquez, Bordeaux, France

Daniel Vasmant, Paris, France

Patrice Jaillon, Paris, France

EUROPEAN SOCIETY FOR DEVELOPMENTAL PHARMACOLOGY

Seventh Congress

November 17th–20th, 2001

Limassol, Cyprus

The Seventh Congress of the European Society will be held in Limassol, Cyprus and will involve the following:

- State of the Art Lectures
- Symposia
- Workshop
- Oral Free Communications Sessions
- Poster Free Communications Session
- Publication of Abstracts

Abstracts accepted for presentation will be published here in *Paediatric and Perinatal Drug Therapy*

Further information from:

Rafael Gorodischer, MD
Department of Pediatrics
Soroka Medical Center
PO Box 151
Beer-Sheva
Israel 84101

Tel. +972-7-6400546
Fax +972-7-6400016
Email: rafaelg@bgumail.bgu.ac.il

Paediatric and Perinatal Drug Therapy

Instructions to Authors

1. All manuscripts should be in the English language. They should be submitted to Professor Imti Choonara, Academic Division of Child Health, University of Nottingham, Derbyshire Children's Hospital, Uttoxeter Road, Derby DE22 3NE, UK (Email: imti.choonara@nottingham.ac.uk). Manuscripts from North America should be submitted to Professor Greg Kearns, Children's Mercy Hospital, 2401 Gilham Road, Kansas City, Missouri 64108, USA (Email: gkearns@cmh.edu). *Paediatric and Perinatal Drug Therapy* is published, produced and distributed by LibraPharm Limited, Gemini House, 162 Craven Road, NEWBURY, Berkshire RG14 5NR, UK. Tel: (0)1635-522651; Fax: (0)1635-36294; email: journals@librapharm.com
2. Submission of manuscripts as both hard-copy and word-processor files facilitates rapid publication. Most common word-processor formats are acceptable, although Microsoft Word is preferred. Typewritten material should be prepared double-spaced and on one side of the paper only. Two copies should be supplied. Any hand-written corrections or photocopies of the original manuscript should be clearly legible. Each paper should contain the following: (a) a short descriptive title, (b) the name(s) and initials of the author(s), (c) the Centre at which the work was carried out or the location of the author(s), (d) a summary or abstract of the main facts and results, (e) an Introduction, (f) separate main sections, (g) a final Discussion or Conclusions section, (h) any acknowledgements and (i) full references to relevant material in the text. Authors are also requested to supply approximately six 'key words', in English, preferably from the Index Medicus Medical Subject Heading (MeSH) list.
3. All drugs and other compounds should be referred to by their internationally accepted generic names and not by individual company trade marks, unless it is essential for clarity, as in the case of combination products, or to avoid confusion, e.g. between different formulations.

Specialised abbreviations and symbols should not be used unless first explained in the text. Dosages and measurements should be given in the units in which they were made, but non-metric units should be accompanied by metric (SI) equivalents.
4. Acknowledgement must be given by authors of grants, fellowships, or any commercial assistance received or of any affiliation which is relevant to the work reported.
5. All references should be individually numbered in Arabic numerals and cited where they appear in the text. At the end of the paper, references should be listed in strict numerical order. The names of all authors for each reference must be given (unless there are six or more, in which case the first three should be listed, followed by 'et al.'). They should be followed by: (a) the full title of the paper, (b) the year of publication, (c) the abbreviated title of the journal (ANSI/BSI system), and (d) the volume and page number(s). Reference to books must give the publisher, place and year of publication, name(s) of the editor(s) where authorship is multiple, and first page number of chapter referred to.
6. All tables and illustrations should be provided with short descriptive legends, numbered consecutively, and their relevant position in the text clearly indicated. Tables should have concise headings to all columns and be identified by Arabic numerals, e.g. Table 2. They should be supplied within the files on disk in cellular form rather than in simple tabbed form. Line diagrams should be supplied both as files on disk in either .TIF or .EPS format and in the format of the program used to produce them. If this is not possible, they should be supplied in a suitable finished form for reproduction and in proportion to the single-column width (80 mm) or double-column width (165 mm). Photographic illustrations will usually be accepted. Illustrations should also be identified by Arabic numerals, e.g. Figure 2.
7. Papers are published on the understanding that their copyright becomes the property of the Publishers once they are accepted for publication. Authors must state clearly if the paper is being actively considered for publication or has been published elsewhere in the world. If subject to copyright (and this includes illustrations), copyright clearance is the sole responsibility of the author and must be supplied in writing to the Publishers. Papers first published in *Paediatric and Perinatal Drug Therapy* must not be translated, abridged or reprinted in any form elsewhere in the world without the written consent of the Publishers.
8. Proofs in page form will be sent to the main author for checking provided that this will not result in delayed publication of any issue of the journal. If, because of postal delays, etc. time is limited, the Publishers reserve the right to have proofs checked against original manuscripts by their editorial staff and/or the editors. No major alterations to text will be accepted at proof stage.